J&J Reports Q1 Results

Johnson & Johnson, which makes Aveeno and Neutrogena and is also working on COVID-10 vaccine candidates, has announced results for first-quarter 2020. 

Worldwide sales were $20.6 billion in the quarter, up 3.3%, according to J&J.
 
J&J’s Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 11.0% to $3.6 billion, driven primarily by over-the-counter products including its Tylenol and Motrin analgesics, upper respiratory products, digestive health products and Zarbee Naturals. Other contributors to growth were Listerine mouthwash in oral care products; Neutrogena and Aveeno in skin health/beauty products, as well J&J’s feminine hygiene products. 
 
“With Johnson & Johnson's century-plus history of leading in times of great challenge, we are mobilizing our resources across the company in the fight against the COVID-19 pandemic,” said Alex Gorsky, chairman and CEO. “Johnson & Johnson is built for times like this, and we are leveraging our scientific expertise, operational scale and financial strength in the effort to advance the work on our lead COVID-19 vaccine candidate. We are committed to beginning production at risk imminently and bringing an affordable and accessible vaccine to the public on a not-for-profit basis for emergency pandemic use.” 
 
Gorsky continued, “I am both proud and amazed at the level of dedication that I have witnessed from our more than 132,000 employees as we have focused on delivering on our commitments and responsibilities to the patients and consumers we serve. Our strong performance in the first quarter reflects the efforts of our teams around the world and the sustainability of our business model.”